Displaying all 2 publications

Abstract:
Sort:
  1. Chellammal HSJ, Hasan MH, Kshirsagar RP, Musukula VKR, Ramachandran D, Diwan PV
    J Diabetes Metab Disord, 2022 Dec;21(2):1415-1426.
    PMID: 36404813 DOI: 10.1007/s40200-022-01074-4
    OBJECTIVES: Glucose intolerance and insulin resistance are hallmarks of metabolic syndrome and lead to Alzheimer's disease (AD). The purpose of this study is to elucidate the neuroprotective effect of metformin through insulin regulation with cardiometabolic and neurotransmitter metabolic enzyme regulation in high-fat, high-sucrose diet and streptozotocin (HFHS-STZ)-induced rats.

    METHODS: Male Wistar rats were treated with metformin (180 mg/kg and 360 mg/kg). STZ (35 mg/kg i.p.) injection was performed on the 14th day of 42 days of HFHS diet treatment. Brain neurotransmitter metabolic enzymes (acetylcholinesterase and monoamine oxidase) were determined along with sodium-potassium ATPase (Na+K+-ATPase). Plasma lipids and homeostasis model assessment of insulin resistance (HOMA-IR) was performed. Mean arterial blood pressure, heart rate and electrocardiogram (QT, QTc and RR intervals) were analysed with PowerLab.

    RESULTS: Metformin treatment significantly (p 

  2. Chellammal HSJ, Hasan MH, Kshirsagar RP, Musukula VKR, Ramachandran D, Diwan PV
    J Diabetes Metab Disord, 2023 Dec;22(2):1813.
    PMID: 37969918 DOI: 10.1007/s40200-023-01229-x
    [This corrects the article DOI: 10.1007/s40200-022-01074-4.].
Related Terms
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links